Browse by Track

(P 01) A PILOT STUDY ON SINGLE-NUCLEUS RNA SEQUENCING IN CANINE SOFT TISSUE SARCOMAS

(P 02) A PRECLINICAL ASSAY PIPELINE TO IDENTIFY AND OPTIMIZE BRACHYURY-TARGETED THERAPIES IN CHORDOMA AND OTHER SOLID TUMORS

(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA

(P 04) CHROMOSOME SPECIFIC ORGANIZATIONAL CHARACTERISTICS IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS

(P 05) DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES

(P 06) DIFFICULTIES IN ASSESSING THE PROGNOSTIC SIGNIFICANCE OF A NOVEL BIOMARKER IN THE CONTEXT OF A TISSUE BANKING STUDY

(P 07) DIRECTLY TARGETING CIC-DUX4 FUSION AND MYC ONCOPROTEINS FOR UNDIFFERENTIATED ROUND CELL SARCOMAS

(P 08) ELUCIDATING THE ROLE OF YAP IN SARCOMA DEVELOPMENT

(P 09) FERROPTOSIS INDUCTION: A BIOCHEMICAL VULNERABILITY OF SOFT TISSUE SARCOMAS

(P 10) GENERATION OF A CHROMOSOME 8 GAIN;NF1-/- HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED SCHWANN CELL PRECURSOR MODEL

(P 11) GENETIC AND EPIGENETIC CHARACTERIZATION OF SARCOMA STEM CELLS ACROSS SUBTYPES IDENTIFIES EZH2 AS A THERAPEUTIC TARGET

(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS

(P 13) GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE

(P 14) HDAC INHIBITORS DOWNREGULATE THE EXPRESSION LEVELS OF THE MINI-CHROMOSOME MAINTENANCE PROTEINS, AND INHIBIT DNA REPLICATION, IN EWING SARCOMA CELLS

(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS

(P 17) IDENTIFICATION OF MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL IN LEIOMYOSARCOMA THROUGH MIRNA SEQUENCING

(P 18) IMMUNOHISTOCHEMICAL ANALYSIS OF NUCLEAR β-CATENIN IN BONE AND SOFT TISSUE TUMOR MICROARRAYS

(P 19) INVOLVEMENT OF O-GLCNAC TRANSFERASE IN RESISTANCE TO DOXORUBICIN AND CELL DEATH IN PRECLINICAL MODELS OF LEIOMYOSARCOMA AND DESMOID TUMORS

(P 20) LEIOMYOSARCOMA OF THE THORACIC AORTA - A RARE CASE REPORT

(P 21) LSD1 INHIBITOR SP-2509 DISRUPTS IRON-SULFUR CLUSTER BIOGENESIS

(P 22) MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA

(P 23) METASTATIC ALVEOLAR SOFT PART SARCOMA: PREGNANCY-RELATED WORSENING AND SPONTANEOUS EXCEPTIONAL REMISSION POSTPARTUM- A CASE REPORT.

(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES

(P 25) PRIMARY TREATED VERSUS REFERRED TRUNK AND EXTREMITIES SOFT TISSUE SARCOMAS: ANALYSIS OF TREATMENT IMPACT IN A SPECIALIZED CENTER IN ARGENTINA.

(P 26) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA

(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS

(P 28) THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK

(P 29) ABDOMINAL LYMPHANGIOMA CAUSING EXCESSIVE GASTROINTESTINAL BLEEDING FOR MORE THAN TWO DECADES

(P 30) CLINICAL BENEFIT OF PEGYLATED-LIPOSOMAL DOXORUBICIN IN THE MANAGEMENT DESMOID TYPE FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE

(P 31) CLINICAL CHALLENGES AND EVOLVING TREATMENT STRATEGIES IN DESMOID FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE

(P 33) DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL

(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE

(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS

(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS

(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB

(P 38) LOCAL RECURRENCE OF DIFFUSE PIGMENTED VILLONODULAR SYNOVITIS IN MAJOR JOINTS: A 15 YEAR-LONG CASE SERIES AT A SINGLE INSTITUTION

(P 39) PATIENT OUTCOMES FOLLOWING MINIMALLY INVASIVE TREATMENT OF ANEURYSMAL BONE CYSTS USING DOXYCYCLINE

(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR

(P 41) PEXIDARTINIB UPFRONT IN A CASE OF TENOSYNOVIAL GIANT CELL TUMOR: PROOF OF CONCEPT FOR A TREATMENT PARADIGM SHIFT

(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS

(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY

(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL

(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS

(P 46) A NEED FOR STANDARDIZATION IN TRIAL DESIGN AND DATA REPORTING IN PHASE II TRIALS IN RARE TUMORS. LESSONS LEARNED FROM PHASE II TRIALS IN BONE SARCOMAS

(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS

(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS

(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY

(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP

(P 51) ASSESSING THE IN VIRTO EFFICACY OF DISULFIRAM AND ENZALUTAMIDE COMBINATION THERAPY IN METASTATIC OSTEOSARCOMA

(P 52) CEMENT-AUGMENTED INTERNAL FIXATION FOR TEMPORIZING BONE SARCOMAS OF THE HIP

(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE

(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA

(P 55) CHONDROSARCOMA PATIENT CHARACTERISTICS AND DIAGNOSTIC AND TREATMENT PATHWAYS: GLOBAL CHONDROSARCOMA PATIENT REGISTRY

(P 56) CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION

(P 57) CLINICAL GENOMIC PROFILING OF MALIGNANT GIANT CELL TUMOR OF BONE: A RETROSPECTIVE ANALYSIS USING A REAL-WORLD DATABASE

(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA

(P 59) COMPREHENSIVE SINGLE CELL TRANSCRIPTOMICS ANALYSIS OF MURINE OSTEOSARCOMA UNCOVERS SKP2 FUNCTION IN METASTASIS, GENOMIC INSTABILITY AND IMMUNE ACTIVATION AND REALS ADDITIONAL TARGET PATHWAYS

(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL

(P 61) DOES CLINICAL PROGRESSION PORTEND POOR ONCOLOGICAL OUTCOMES IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY

(P 62) DOES LIQUID NITROGEN RECYCLED AUTOGRAFT FOR TREATMENT OF BONE SARCOMA IMPACT LOCAL RECURRENCE RATE? A SYSTEMATIC REVIEW

(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER

(P 64) ENTINOSTAT ENHANCES PRO-INFLAMMATORY CHEMOKINE PRODUCTION AND INCREASES RADIATION-INDUCED APOPTOSIS IN EWING SARCOMA

(P 65) EPIGENETIC HETEROGENEITY AND STATE SPECIFIC TRANSCRIPTIONAL PROGRAMS DRIVE DRUG RESPONSE IN OSTEOSARCOMA

(P 66) EWING TUMORS WITH STAG2 LOSS DEMOSNTRATE ALTERED INTERFERON SIGNATURES AND IMPAIRED CXCL10 EXPRESSION

(P 67) EXTERMITY SOFT TISSUE SARCOMA -RETROSPECTIVE ANALYSIS OF 21YEARS EXPERIENCE IN A TERTITARY CARE CENTRE.

(P 68) FEASIBILITY OF FIVE-DRUG INTERVAL-COMPRESSED CHEMOTHERAPY FOR ADOLESCENTS AND YOUNG ADULTS WITH EWING SARCOMA FAMILY TUMORS IN THE REAL-WORLD SETTING IN OMAN

(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA

(P 70) IDENTIFICATION OF NOVEL PROTEIN VARIANTS IN OSTEOSARCOMA TUMORS THROUGH LONG-READ RNA SEQUENCING

(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER

(P 72) LIVE-CELL TISSUE MODELS REVEAL SOURCES OF DYNAMIC HETEROGENEITY IN THE OSTEOSARCOMA METASTATIC NICHE

(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA

(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA

(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS

(P 76) MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT

(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA

(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE

(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT

(P 80) OUTCOMES AND MANAGEMENT OF POSITIVE MARGINS IN CHONDROSARCOMA WITH SOFT TISSUE EXTENSION: A CASE SERIES AND REVIEW OF LITERATURE

(P 81) OUTCOMES DATA FOR OSTEOSARCOMA PATIENTS OVER AGE 60

(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA

(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT

(P 84) PROGNOSTIC IMPLICATIONS OF PATHOLOGICAL FRACTURES IN EXTREMITY OSTEOSARCOMA: A RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES AND LIMB-SALVAGE FEASIBILITY

(P 85) PTEROSTILBENE SENSITIZES OSTEOSARCOMA CELLS TO KILLING BY C-MYC INHIBITORS

(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL

(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA

(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS

(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?

(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL

(P 91) THE EFFECT OF CHEMOTHERAPY AND SURGERY TIMING ON MORTALITY IN THE TREATMENT OF UPPER AND LOWER EXTREMITY OSTEOSARCOMA: A DATABASE STUDY

(P 92) THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES

(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA

(P 94) THE ROLE OF CMYC AMPLIFICATION VERSUS CMYC PROTEIN EXPRESSION AS A PROGNOSTIC BIOMARKER IN OSTEOSARCOMA

(P 96) TRACP-5B AS A BIOMARKER FOR LONG-TERM DENOSUMAB TREATMENT OF UNRESECTABLE GIANT CELL TUMOR OF BONE

(P 97) TRANSCRIPTOMICS REVEALS THAT OVEREXPRESSION OF LNCRNA HOTTIP REGULATES PKC PROTEIN ACTIVATION OF THE RAP1 SIGNALING PATHWAY FOR SYNOVIAL SARCOMA CELL PROGRESSION

(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH

(P 99) ACQUIRED NF2 MUTATION CONFERS RESISTANCE TO TRK INHIBITION IN AN EX VIVO LMNA::NTRK1-REARRANGED SOFT TISSUE SARCOMA CELL MODEL

(P 100) ADVANCING PROGNOSTICS IN ONCOLOGY: MACHINE LEARNING MODELS FOR PREDICTING 2-YEAR AND 5-YEAR SURVIVAL RATES IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)

(P 102) ANALYSIS OF BLOOD-BASED BIOMARKERS AS PROGNOSTIC FACTORS IN PATIENTS WITH EHE TREATED WITH TRAMETINIB IN SARC033

(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA

(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT

(P 105) CLINICAL OUTCOMES OF SUB-CENTIMETRIC LUNG NODULES IN PATIENTS WITH EXTREMITY OSTEOSARCOMA: A RETROSPECTIEV COHORT STUDY

(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS

(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

(P 108) FIXATION OF IMPENDING OR PATHOLOGIC FRACTURES DUE TO METASTATIC DISEASE WITH CARBON FIBER INTRAMEDULLARY NAILS-A PROPENSITY-SCORE MATCHED COST ANALYSIS

(P 109) INTEGRATED TRANSCRIPTOMIC ANALYSIS OF CIC::DUX4 FUSION SARCOMAS REVEALS ELEVATED PROLIFERATION SIGNALING AND IMPLICATES DNA REPAIR GENE POLE

(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE

(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE

(P 112) MACHINE LEARNING ANALYSIS TO DEFINE CELL LINEAGE IN LEIOMYOSARCOMA

(P 113) METASTATIC EWING'S TRAIL TESTING SCHEDULE ENHANCEMENT TO IMPROVE OUTCOMES (METTSEO)

(P 114) METHYLOME PROFILING OF CARTILAGE TUMOURS: A PROMISING NEW TOOL FOR BIOPSY MATERIAL?

(P 115) PROSPECTIVE EVALUATION OF THORACOSCOPIC METASTASECTOMY IN DOGS: A NOVEL TRANSLATIONAL DRUG DEVELOPMENT PIPELINE TAGETING METASTATIC OSTEOSARCOMA

(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA

(P 118) UNRAVELING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY AND THERAPEUTIC OPPORTUNITIES IN SOFT TISSUE AND BONE SARCOMA

(P 119) UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 120) USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA

(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA

(P 122) ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE

(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA

(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY

(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010

(P 126) CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES

(P 127) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES

(P 128) DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS

(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING

(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.

(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL

(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY

(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING

(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA

(P 135) SURVIVAL OUTCOMES AND TREATMENT PATTERNS FOR PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: A RETROSPECTIVE COHORT STUDY IN ONTARIO, CANADA

(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA

(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS

(P 138) ACCURACY AND COMPLICATIONS OF CORE NEEDLE BIOPSY OF PERIPHERAL NERVE TUMORS

(P 139) CHARACTERIZATION OF GLYCOSPHINGOLIPIDS IN HUMAN LEIOMYOSARCOMA

(P 140) CIRCULATING TUMOR DNA AS A TOOL OF SURVEILLANCE AND EARLY INDICATOR OF RELAPSE IN SARCOMA PATIENTS

(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY

(P 142) CORE NEEDLE BIOPSY OF PERIACETABULAR CHONDROSARCOMA OFTEN RESULTS IN UNDER-GRADING BUT DOES NOT CHANGE MANAGEMENT BY EXPERIENCED ORTHOPAEDIC ONCOLOGISTS.

(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS

(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA

(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)

(P 146) EXPLORING THE CLINICAL UTILITY OF WHOLE GENOME SEQUENCING FOR PAEDIATRIC, TYA AND ADULT SARCOMA PATIENTS WITHIN THE LONDON SARCOMA SERVICE: A RETROSPECTIVE COHORT ANALYSIS

(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION

(P 148) ISOCITRATE DEHYDROGENASE MUTATIONS IN CHONDROSARCOMA: A META-ANALYSIS

(P 149) LACK OF CORRELATION OF FDG-PET/CT SUV MAXIMUM AND MALIGNANT TRANSFORMATION IN NEUROFIBROMATOSIS TYPE 1-RELATED PLEXIFORM NEUROFIBROMAS

(P 150) MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP

(P 151) MOLECULAR ANALYSIS OF CUTANEOUS SARCOMATOID NEOPLASMS FREQUENTLY IDENTIFIES MELANOMA DRIVER VARIANTS

(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES

(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE

(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING

(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE

(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS

(P 157) REAL WORLD CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS

(P 158) RECURRENT RADIATION-INDUCED SARCOMA IN A PATIENT WITH HEREDITARY RETINOBLASTOMA: PRESENTATION AND OUTCOME

(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL

(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION

(P 161) UTILITY OF CTDNA MONITORING IN THE ADJUVANT AND METASTATIC SETTING IN SOFT TISSUE SARCOMA

(P 162) ANALYSIS OF 3,144 CASE REPORTS IN THE GASTROINTESTINAL STROMAL TUMOR LITERATURE: IDENTIFICATION OF UNDERAPPRECIATED DEMOGRAPHICS, CLINICAL PRESENTATIONS, AND BIOLOGY

(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS

(P 164) CLINICAL BENEFITS OF RIPRETINIB AND CYTOREDUCTIVE SURGERY IN IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A RETROSPECTIVE DUAL-CENTER STUDY

(P 165) COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL

(P 166) D842V - A TALE OF TWO STAGES: COMPARATIVE ANALYSIS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN GIST PATIENTS WITH PDGFRA D842V MUTATIONS

(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH

(P 168) EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION

(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)

(P 170) GASTRIN RELEASING PEPTIDE RECEPTOR EXPRESSION IN GASTROINTESTINAL STROMAL TUMORS (GIST)

(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY

(P 172) GIST WITH ATYPICAL MORPHOLOGY INITIALLY MISDIAGNOSED-THE IMPORTANCE OF BROAD IMMUNOCHEMISTRY-A CASE REPORT

(P 173) IN VITRO PROFILING OF IDRX-42 AGAINST SECONDARY MUTATIONS FOUND IN TKI-RESISTANT GIST

(P 174) INCIDENCE, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) IN ALBERTA, CANADA FROM 2008 - 2022.

(P 175) KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE

(P 176) LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS

(P 177) PREDICTING THE IMATINIB RESPONSE OF PDGFRA EXON 18-MUTANT GASTROINTESTINAL STROMAL TUMOR USING IN VITRO MODELS

(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)

(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY

(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY

(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE

(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM

(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES

(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS

(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE

(P 186) ANALYSIS OF FACTORS INFLUENCING POSTOPERATIVE VENOUS THROMBOEMBOLISM FORMATION IN PATIENTS WITH MASSIVE BLOOD LOSS DURING RETROPERITONEAL TUMOR RESECTION

(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS

(P 188) BURDENS OF A CAREGIVER TO SARCOMA PATIENT AND HOW TO REDUCE THEM

(P 189) CLEAR CELL SARCOMA - REAL WORLD DATA ANALYSIS

(P 190) CLINICAL FEATURES ASSOCIATED WITH DIFFERENT HISTOLOGICAL SUBTYPES OF SARCOMA: A POPULATION-BASED STUDY OF 97062 CASES

(P 191) CLINICOPATHOLOGICAL CHARACTERISTICS OF ANGIOSARCOMA AND THE RISK OF MULTIPLE PRIMARY MALIGNANCIES

(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP

(P 193) DISTRIBUTION OF CONNECTIVE TISSUE TUMORS BY HISTOLOGY AND DEGREE OF MALIGNANCY IN A SINGLE INSTITUTION IN OMAN

(P 194) EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)

(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS

(P 196) ESTABLISHING THE BONE CANCER RESEARCH TRUST'S PATIENT & PUBLIC INVOLVEMENT PANEL

(P 197) EVALUATION OF REVIEWS OF ORTHOPAEDIC ONCOLOGISTS ON INSTITUITIONAL AND PATIENT REVIEW WEBSITES

(P 198) FACTORS INFLUENCING TIME TO TREATMENT INITIATION IN PROMARY EXTREMITY SARCOMA: A RETROSPECTIVE ANALYSIS

(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS

(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY

(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS

(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1

(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS

(P 204) IMPACT OF UNPéLANNED EXCISION ON THE SURVIVAL OF SARCOMA PATIENTS - A TARGET TRIAL EMULATION

(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA

(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA

(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH

(P 209) RACE AND ETHNICITY ON DIAGNOSIS, METASTASIS, AND MORTALITY OF SOFT TISSUE SARCOMAS IN RETROSPECTIVE COHORT STUDY

(P 210) RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS

(P 211) REAL-WORLD EXPERIENCE OF PATIENTS NEWLY INITIATED ON PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR

(P 212) REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK

(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP

(P 214) REPRESENTATION OF CHILDREN AND OLDER ADULTS IN SARCOMA CLINICAL TRIALS SINCE THE INCLUSION ACROSS THE LIFESPAN POLICY

(P 215) REPRESENTATION OF RACIAL AND ETHNIC MINORITIES IN SARCOMA CLINICAL TRIALS

(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP

(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP

(P 218) SEX DIFFERENCES IN THE ASSOCIATION OF ALCOHOL INTAKE WITH THE RISK OF SOFT-TISSUE SARCOMA: A NATIONWIDE POPULATION-BASED RETROSPECTIVE COHORT STUDY

(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP

(P 220) SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS

(P 221) 8+ YEARS OF IMMUNOTHERAPY FOR METASTATIC ALVEOLAR SOFT PART SARCOMA

(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA

(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES

(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS

(P 225) DETERMINING THE CONTRIBUTIONS OF STAT1 AND THE Y701 PHOSPHORYLATION TO THE UPS ANTI-TUMOR MICROENVIRONMENT

(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA

(P 227) EFFICACY OF IMMUNOTHERAPY IN TREATING METASTATIC MALIGNANT MYOPERICYTOMA: A CASE REPORT AND RIVEW OF LITERATURE

(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION

(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA

(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY

(P 232) IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS

(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION

(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY

(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS

(P 236) INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS

(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA

(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA

(P 239) INVESTIGATING HOW TUMOUR ASSOCIATED MACROPHAGES INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF SOFT TISSUE SARCOMA

(P 240) INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES

(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)

(P 242) MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW

(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY

(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA

(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA

(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES

(P 247) THE REAL-WORLD EFFICACY OF IMMUNE CHECKPOINT INHIBITORS WITH CONCURRENT RADIATION OR SURGERY IN MULTIMODAL TREATMENT OF SOFT TISSUE SARCOMAS: A RETROSPECTIVE STUDY

(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)

(P 249) TUMOR CELL DISAPPEARANCE FOLLOWING COVID-19 INFECTION IN A PATIENT WITH PLEOMORPHIC SPINDLE CELL SARCOMA: A CASE REPORT

(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)

(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)

(P 252) A NOVEL MULTIDISCIPLINARY SURGICAL APPROACH TO PERIPHERAL NERVE SHEATH TUMORS AND SOFT TISSUE SARCOMAS.

(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY

(P 254) ATYPICAL FEMUR FRACTURE IN A TEENAGER ON CHRONIC IMATINIB THERAPY

(P 255) CAN LARGE, LIPOMATOUS LESIONS ADJACENT TO THE SUPINATOR MUSCLE BE REMOVED WITHOUT INJURING THE POSTERIOR INTEROSSEOUS NERVE? A RETROSPECTIVE REVIEW

(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE

(P 259) COMPRESSION OF INTERCALARY ALLOGRAFTS WITH MAGNETIC LENGTHENING NAILS, MID-TERM RESULTS WITH A COMPARISON OF TECHNIQUES

(P 260) EMERGING TECHNOLOGY IN ORTHOPEDIC ONCOLOGY: ROBOTIC ARM-ASSISTED TOTAL KNEE ARTHROPLASTY HAS EXCEPTIONAL FUNCTION OUTCOMES FOR PATIENTS WITH BENIGN AND MALIGNANT MUSCULOSKELETAL DISEASE

(P 261) EVALUATION OF CT ARTIFACTS AFTER SPINAL OLIGOMETASTATIC DISEASE RESECTION AND RECONSTRUCTION: A COMPARATIVE STUDY OF CARBON-FIBER VS. TITANIUM IMPLANTS

(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS

(P 263) HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION

(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?

(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?

(P 266) LONG STEM CEMENTED ROBTIC ARM-ASSISTED TOTAL HIP ARTHROPLASTY: OUTCOMES IN PATIENTS WITH PRIOR ONCOLOGIC DISEASE

(P 267) LONG-TERM FUNCTIONAL OUTCOMES OF SHOULDER ARTHRODESIS FOR TUMOR RESECTION

(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA

(P 269) LYMPHOEDEMA FOLLOWING LIMB SALVAGE SURGERY FOR EXTREMITY SARCOMA: A RETROSPECTIVE ANALYSIS OF 282 PATIENTS

(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES

(P 271) OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR

(P 272) OUTCOMES OF FOUR CASES OF TOTAL HIP ARTHROPLASTY (THA) WITH POROUS TANTALUM IMPLANT AFTER PARTIAL ACETABULAR RESECTION USING 3D PREOPERATIVE PLANNING FOR PELVIC BONE TUMORS

(P 273) PRIMARY SOFT-TISSUE SARCOMAS OF THE UPPER LIMBS

(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)

(P 275) RECONSTRUCTION WITH A BURCH-SCHNEIDER CAGE AFTER BONE AND SOFT TISSUUE TUMOR SURGERY

(P 276) RECONSTRUCTION WITH TOTAL SCAPULAR REVERSE TOTAL SHOULDER ENDOPROSTHESIS: PRELIMINARY RESULTS FROM A SINGLE INSTITUTE

(P 277) REVERSE TOTAL SHOULDER ARTHROPLASTY MAINTAINS GLOBAL FUNCTION OF THE UPPER EXTREMITY IN PATIENTS WITH ONCOLOGIC DISEASE OF THE PROXIMAL HUMERUS

(P 278) ROTATIONPLASTY AS AN EFFECTIVE LIMB SALVAGE OPTION IN THE ADULT POPULATION

(P 279) SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR

(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION

(P 282) UNPLANNED RESECTION OF SOFT TISSUE SARCOMA: THE IMPACT OF RESIDUAL DISEASE IN RE-RESECTION SPECIMEN

(P 283) USE OF MIXED REALITY IN PELVIC BONE TUMOR RESECTION: FIVE CASE STUDY

(P 284) WOUND VAC TEMPORIZATION AFTER TUMOR RESECTION OF SOFT TISSUE SARCOMAS - A COST ANALYSIS IN A PROPENSITY-SCORE MATCHED POPULATION

(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS

(P 286) ADAMANTINOMA - LIKE EWING SARCOMA WITH ATYPICAL PRESENTATION AND FATAL OUTCOME IN 20-YEAR-OLD WOMAN - A CASE REPORT

(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA

(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS

(P 289) APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES

(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY

(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA

(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS

(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY

(P 294) COMPARING HIGH-GRADE NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA IN ADULT AND PEDIATRIC POPULATIONS

(P 295) DEFINING OSTEOSARCOMA HETEROGENEITY: CONSENSUS CLUSTERING REVEALS GENE EXPRESSION SUBTYPES

(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER

(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES

(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES

(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?

(P 300) GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS

(P 301) GENOME-WIDE CRISPR/CAS9 VIABILITY SCREENS UNCOVER NOVEL GENETIC DEPENDENCIES IN CIC::DUX4 SARCOMA

(P 302) HER2 PRETARGETED ALPHA PARTICLE RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS

(P 303) INVESTIGATING THE THERAPEUTIC POTENTIAL OF TRIPTOLIDE PRODRUG, MINNELIDE, AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA

(P 304) LOCAL CONTROL FOR PEDIATRIC RHABDOMYOSARCOMA OF THE EXTREMITIES. IS RADIOTHERAPY ALWAYS REQUIRED AFTER ADEQUATE SURGICAL RESECTION?

(P 305) LOCAL THERAPY APPROACHES IN RELAPSED PEDIATRIC SOFT TISSUE SARCOMA AND EWING SARCOMA PATIENTS: A SINGLE INSTITUTION SERIES

(P 306) LONG TERM OUTCOMES OF TYPE BIIIA ROTATIONPLASTY AFTER TOTAL FEMUR EXCISION IN CHILDREN

(P 307) OUTCOMES OF PEDIATRIC NON-RHABDOMYOSARCOMA SOFT-TISSUE SARCOMAS OF THE EXTREMITIES

(P 308) PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS

(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

(P 310) PROGNOSTICATION AND EPIDEMIOLOGY OF CLEAR CELL SARCOMA: A SEER STAT RETROSPECTIVE ANALYSIS

(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS

(P 312) RARE CASE OF INTRAOSSEOUS RHABDOMYOSARCOMA IN A YOUNG CHILD

(P 313) RELATION BETWEEN NUTRITIONAL/INFLAMMATORY PARAMETERS AND PROGNOSIS IN CHILDHOOD SARCOMA PATIENTS

(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY

(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA

(P 316) SECONDARY RHABDOMYOSARCOMA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS

(P 317) SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE

(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE

(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY

(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY

(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY

(P 322) A NEW PLAYER IN SOFT TISSUE SARCOMA PROGRESSION: WNT5A IS A PROGNOSIS BIOMARKER AND A POTENTIAL ACTIONABLE TARGET

(P 323) AN IN-VITRO INVESTIGATION OF 5-AMINOLEVULINIC ACID MEDIATED PHOTODYNAMIC THERAPY IN SOFT-TISSUE SARCOMA

(P 324) BENZIMIDAZOLE DERIVATIVES AS NOVEL THERAPEUTIC AGENTS FOR INI1-DEFICIENT EPITHELIOID SARCOMA

(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT

(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS

(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA

(P 328) DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER

(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS

(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA

(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA

(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS

(P 333) ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE

(P 335) FOCAL ADHESION KINASE (FAK) IS A THERPEUTIC TARGET IN CHROMOSOME 8 GAIN-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)

(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA

(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA

(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS

(P 339) SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201

(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA

(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA

(P 342) THE ROLE OF MYELOPEROXIDASE IN SARCOMA TREATMENT

(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS

(P 344) TRANSCRIPTOMIC ANALYSIS OF DESMOID TUMOR RESPONSE TO NIROGACESTAT: NOVEL MECHANISMS OF RESISTANCE?

(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.

(P 346) BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS

(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?

(P 348) EVALUATING THE IMPACT OF BIOLOGICAL EFFECTIVE DOSE AND DELAYED RADIOTHERAPY ON THE SYNERGISTIC EFFICACY OF TRABECTEDIN IN METASTATIC SOFT TISSUE SARCOMA PATIENTS

(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA

(P 350) MONITORING CHANGES IN FEMORAL BONE STRENGTH IN PATIENTS WITH METASTATIC BONE DISEASE TREATED WITH RADIATION THERAPY

(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE

(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA

(P 354) PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS

(P 355) PROTON RADIOTHERAPY FOR DESMOID TUMORS: A SINGLE-CENTER EXPERIENCE

(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA

(P 357) RADIATION THERAPY OF EXTREMITY SOFT TISSUE SARCOMAS: A NATIONWIDE COHORT STUDY OF LATE SIDE EFFECTS - TRIAL IN PROGRESS

(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY

(P 359) RAPIDLY PROGRESSIVE, NON-METASTATIC, CUTANEOUS ANGIOSARCOMA OF FACE AND SCALP TREATED WITH HYPOFRACTIONATED RADIATION THERAPY: A CASE SERIES

(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY

(P 361) WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS

(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY

(P 363) A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION

(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA

(P 365) A SINGLE INSTITUTION COMPARISON OF OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH GYNECOLOGIC ORIGIN RHABDOMYOSARCOMA

(P 366) ABDOMINAL AORTA RESECTION EN-BLOC WITH PRIMARY RETROPERITONEAL SOFT-TISSUE SARCOMA AND BI-ILIAC GRAFT RECONSTRUCTION.

(P 367) AGE AS A PROGNOSTIC FACTOR IN RETROPERITONEAL SARCOMA: A MULTICENTER LATIN AMERICAN STUDY

(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER

(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA

(P 370) DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION

(P 371) ELUCIDATING THE CLINICAL UTILITY OF TARGETED GENE EXPRESSION PROFILING IN RETROPERITONEAL LIPOSARCOMA

(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS

(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE

(P 374) FACTORS ASSOCIATED WITH RECURRENCE IN DEDIFFERENTIATED RETROPERITONEAL LIPOSARCOMA: ANALYSIS AT A REFERENCE CENTER

(P 375) FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE

(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA

(P 377) INCIDENCE, RISK FACTORS, AND EFFECT ON 60-DAYS SURVIVAL OF ACUTE KIDNEY INJURY OCCURRED WITHIN 7 DAYS AFTER SURGERY IN ELDERLY PATIENTS WITH RETROPERITONEALL TUMORS: A RETROSPECTIVE COHORT STUDY

(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG

(P 379) KEY POINTS OF ANESTHESIA MANAGEMENT AND PROGNOSIS ANALYSIS OF ELDERLY PATIENTS WITH RETROPERITONEAL TUMOR

(P 380) MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE

(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL

(P 382) PARAGANGLIOMA AND CONGENITAL HEART DISEASE - A RARE CASE REPORT

(P 383) PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY

(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR

(P 385) SIMULTANEOUS OCCURRENCE OF MANTLE CELL LYMPHOMA AND LIPOSARCOMA IN THE RETROPERITONEUM

(P 386) SOLITARY FIBROUS TUMOUR: A DANISH SAMPLE FROM 2013 – 2018

(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT

(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?

(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA

(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG

(P 391) VISCERAL ANGIOSARCOMA: A NATIONWIDE STUDY WITH LONG-TERM FOLLOW-UP

(P 392) ATRX LOSS IN UTERINE LEIOMYOSARCOMA IS ASSOCIATED WITH WORSE OVERALL SURVIVAL AND A DISTINCT PATTERN OF GENE EXPRESSION ACROSS SUBTYPES

(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS

(P 394) IDENTIFYING THE INTERACTOME OF THE ONCOGENIC FUSIONS OF SARCOMAS TO REVEAL NOVEL THERAPEUTIC TARGETS

(P 395) INTEGRATED EPIGENETIC ANALYSES IDENTIFY A MULTI-SARCOMA DNA METHYLATION SIGNATURE OF TUMOR PROGRESSION AND METASTASIS

(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS

(P 397) MTOR ACTIVITY: A BIOMARKER FOR CHEMO- AND IMMUNOTHERAPY RESPONSE AND OUTCOMES IN SARCOMAS

(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB

(P 399) SIMILARITY NETWORK FUSION IDENTIFIES DNA METHYLATION SUBTYPES OF LEIOMYOSARCOMA ASSOCIATED WITH CLINICAL OUTCOME

(P 400) A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT

(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)

(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS

(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY

(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL

(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY

(P 406) LONG-TERM DENOSUMAB THERAPY IN GIANT CELL TUMOR PATIENTS MAY POTENTIALLY LEAD TO THE DEVELOPMENT OF OTHER PRIMARY TUMORS: AN INITIAL OBSERVATION

(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.

(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA

(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY

(P 411) PROPANE AN OPEN LABEL PHASE 2 STUDY ON PROPRANOLOL AND PEMBROLIZUMAB IN ADVANCED ANGIOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA A SCANDINAVIAN SARCOMA GROUP COLLABORATION

(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY

(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)

(P 414) TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®

(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.

(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY

(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS

(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS

(P 419) BONE MECHANICS INFLUENCE CANCER STEM CELL FORMATION IN OSTEOSARCOMA

(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES

(P 421) CHARACTERIZATION OF INTRA-PATIENT, INTER-LESIONAL RESPONSE AND RESISTANCE DYNAMICS IN METASTATIC, FUSION-POSITIVE RHABDOMYOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA

(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA

(P 424) CROSS-COHORT INTEGRATION AS A STRATEGY TO CLASSIFY IMMUNE CHECKPOINT BLOCKADE RESPONSE IN SARCOMA

(P 425) EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA

(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS

(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY

(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES

(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.

(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA

(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.

(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.

(P 433) TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS

(P 434) UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE